AstraZeneca, a global biopharmaceutical company, has announced the launch of Evinova, a health-tech business aimed at accelerating innovation in the life sciences sector. Evinova will operate as a separate entity within AstraZeneca and will focus on delivering digital health solutions to improve clinical trials and enhance health outcomes.

The digital health solutions offered by Evinova will be evidence-led, science-based, and driven by human experience. These solutions will cater to clinical trial sponsors, clinical research organizations (CROs), clinical trial site care teams, and patients. Evinova aims to bring these innovative digital products and services to the broader healthcare community, including healthcare professionals, regulators, and patients.

To ensure the widespread availability of its digital health solutions, Evinova has formed strategic collaborations with globally-leading CROs, Parexel and Fortrea. These collaborations will enable Evinova's digital health solutions to be offered to a wide customer base, fostering industry adoption and expanding their reach.

One of Evinova's primary objectives is to optimize clinical trial design and delivery, reducing the time and cost associated with developing new medicines. By leveraging established digital technology solutions already utilized by AstraZeneca, Evinova aims to bring care closer to patients' homes and alleviate the burden on healthcare systems. Additionally, Evinova intends to explore opportunities in digital remote patient monitoring and digital therapeutics, with a pipeline of digital innovations in these areas.

Drawing on AstraZeneca's extensive experience in developing novel therapeutics and insights from thousands of patients and clinical researchers, Evinova will provide established technology solutions to pharma, biotech, and CROs to support clinical research globally. These technologies have already demonstrated success in delivering multiple AstraZeneca-sponsored clinical trials in more than 40 countries.

Pascal Soriot, the CEO of AstraZeneca, believes that digital solutions have the potential to accelerate the future of medicine development. Soriot stated, "We believe Evinova's combination of scientific expertise and track record in developing AI-enabled digital technologies at scale provides a real opportunity to fundamentally improve patient care, drive healthcare transformation, and reduce carbon emissions."

Cristina Duran, the President of Evinova, expressed excitement about bringing AstraZeneca's digitally-scaled solutions to the broader life sciences community. Duran stated, "We believe this will help propel the sector forward in digital health, as we know healthcare professionals and regulators need digital solutions that work across pharma and support patients broadly. Evinova will be uniquely placed to deliver science-based, evidence-led, and human experience-driven solutions with the aim of improving patient experience and outcomes."

In a significant boost to Evinova's reach, it has partnered with globally-leading CROs, Parexel and Fortrea, to offer its digital health solutions to their wide customer base. Additionally, collaborations with Accenture and Amazon Web Services will help promote industry adoption of Evinova's digital products and expand their global reach.

Evinova's portfolio includes a comprehensive suite of digital solutions co-created with patients, known as the Evinova drug development suite. This suite includes the Evinova unified trial solution, a globally validated platform that improves the delivery of clinical trials and enhances the patient experience. It enables traditional, hybrid, and decentralized clinical trials, supporting the direct collection of primary and secondary endpoint data, virtual visits, and patient monitoring.

Another offering is the Evinova study design and planning module, which uses AI and machine learning algorithms to optimize clinical trial design based on real-world data. Evinova also provides portfolio management solutions that offer real-time insights and predictive analytics, enabling study leaders to track and manage clinical programs and trials effectively.

The application of digital health technologies is seen as a solution to reduce healthcare costs while improving patient experience and outcomes. The digital health market is projected to reach over $900 billion by 2032, with a significant portion focused on R&D digital health and care delivery, including remote patient monitoring.

Clinical trials play an essential role in the drug development and approval process, but they can be time-consuming and costly. With the implementation of digital health technology, AstraZeneca has demonstrated that patient experience can be improved, timelines can be accelerated, and costs can be reduced. Evinova aims to build upon these advancements and further revolutionize the clinical trial process.

AstraZeneca, a global leader in the biopharmaceutical industry, continues to drive innovation with the launch of Evinova. With its commitment to science-based expertise, evidence-led rigour, and human experience-driven insight, Evinova is poised to make significant contributions to the digital health landscape, ultimately improving patient outcomes and transforming healthcare.